Related references
Note: Only part of the references are listed.The miR-15a/16 gene cluster in human cancer: A systematic review
Ting Liu et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
KCNQ1OT1/miR-217/ZEB1 feedback loop facilitates cell migration and epithelial-mesenchymal transition in colorectal cancer
Yinzhu Bian et al.
CANCER BIOLOGY & THERAPY (2019)
lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway
Yongchao Li et al.
ONCOTARGETS AND THERAPY (2019)
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Xiangfeng Shen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
Meenal Sharma et al.
MEDICINE (2019)
KCNQ1OT1 facilitates progression of non-small-cell lung carcinoma via modulating miRNA-27b-3p/HSP90AA1 axis
Zhiwu Dong et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer
Florent Petitprez et al.
EUROPEAN UROLOGY FOCUS (2019)
PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation
Xin Yao Qiu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-β signaling pathway
Wei Jin et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression
Kimberley Kolijn et al.
CANCER RESEARCH (2018)
LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling
Shanyi Zhang et al.
CELL DEATH & DISEASE (2018)
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Pedro Isaacsson Velho et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Dysregulation of KCNQ1OT1 promotes cholangiocarcinoma progression via miR-140-5p/SOX4 axis
Hongwei Sun et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2018)
YY1-induced upregulation of lncRNA KCNQ1OT1 regulates angiotensin II-induced atrial fibrillation by modulating miR-384b/CACNA1C axis
Caijie Shen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
The Dysregulated Expression of KCNQ1OT1 and Its Interaction with Downstream Factors miR-145/CCNE2 in Breast Cancer Cells
Weiliang Feng et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Marcus Ruscetti et al.
SCIENCE (2018)
Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location
Harold Evelyn Taitt
AMERICAN JOURNAL OF MENS HEALTH (2018)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Steven C. Kao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Differential methylation of lncRNA KCNQ1OT1 promoter polymorphism was associated with symptomatic cardiac long QT
Eliecer Coto et al.
EPIGENOMICS (2017)
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
Nora Ness et al.
ONCOTARGET (2017)
Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
Song Xue et al.
ONCOTARGET (2017)
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Heidrun Gevensleben et al.
CLINICAL CANCER RESEARCH (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries
Martin C. S. Wong et al.
EUROPEAN UROLOGY (2016)
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
Chan-Young Ock et al.
ONCOTARGET (2016)
Positive feedback regulation between IL10 and EGFR promotes lung cancer formation
Tsung-I Hsu et al.
ONCOTARGET (2016)
PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
Heidrun Gevensleben et al.
ONCOTARGET (2016)
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
Hidetoshi Sumimoto et al.
PLOS ONE (2016)
Regulation of functional KCNQ1OT1 lncRNA by β-catenin
Naohiro Sunamura et al.
SCIENTIFIC REPORTS (2016)
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer
Harshita B. Gupta et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
A. M. Martin et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
PD-1 and PD-L1 antibodies for melanoma
Katy K. Tsai et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The miR-15a-miR-16-1 Locus is Homozygously Deleted in a Subset of Prostate Cancers
Kati P. Porkka et al.
GENES CHROMOSOMES & CANCER (2011)
Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer
M. Musumeci et al.
ONCOGENE (2011)
miR-15a and miR-16-1 in cancer: discovery, function and future perspectives
R. I. Aqeilan et al.
CELL DEATH AND DIFFERENTIATION (2010)
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
Desiree Bonci et al.
NATURE MEDICINE (2008)
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells
Neeraj K. Saxena et al.
CANCER RESEARCH (2007)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Share Paper
